Advertisement

An Asthma Policy Model

  • A. David Paltiel
  • Karen M. Kuntz
  • Scott T. Weiss
  • Anne L. Fuhlbrigge
Part of the International Series in Operations Research & Management Science book series (ISOR, volume 70)

Summary

Despite many proven advances in patient care over the last 10 years, asthma continues to impose a large and growing burden on society. Persistent clinician non-adherence to recommended practice is well documented, but little is known about the clinical impact and economic costs of alternative approaches to asthma patient care. In this chapter, we introduce the Asthma Policy Model, a state-transition simulation that we have developed to forecast asthma-related symptoms, acute exacerbations, quality-adjusted life expectancy, health care costs, and cost-effectiveness. We begin with a detailed survey of the epidemiological, clinical, and policy context that motivates our work. With a modeling audience in mind, we then describe the considerations that produced the current analytic structure and input datasets. We illustrate the policy relevance of the model by describing our recent work on the cost-effectiveness of inhaled corticosteroid therapy in a population of adult patients with mild-to-moderate disease. We close the chapter with a discussion of plans for future refinements and applications.

Key words

Asthma Inhaled corticosteroids Cost-effectiveness analysis Decision analysis Markov models State transition models 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    National Asthma Education and Prevention Program (1997). Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 2, Publication # 97-4051, U.S. Department of Health and Human Services, Washington, DC.Google Scholar
  2. [2]
    Mack, H., P. Johnson, H. Abbey, and R.C. Talcerno (1982). Prevalence of asthma and health service utilization of asthmatic children in a inner city. Journal of Allergy and Clinical Immunology, 70, 367–372.Google Scholar
  3. [3]
    Halfon, N. and P.W. Newacheck (1986). Trends in the hospitalization of acute childhood asthma, 1970–1984. American Journal of Public Health, 76, 1308–1311.Google Scholar
  4. [4]
    Evans, R. 3rd, D.E. Mullally, R.W. Wilson, P.J. Gergen, H.M. Rosenberg, J.S. Grauman, F.M. Chevarley, and M. Feinleib (1987). National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization, and death from asthma over two decades: 1965–1984. Chest, 91, 65S–74S.PubMedGoogle Scholar
  5. [5]
    Sly, R.M. (1988). Mortality from asthma, 1979–1984. Journal of Allergy and Clinical Immunology, 82, 705–717.Google Scholar
  6. [6]
    Weiss, K.B., P.J. Gergen, and E.F. Crain (1992). Inner-city asthma. The epidemiology of an emerging US public health concern. Chest, 101, 362S–367S.PubMedGoogle Scholar
  7. [7]
    National Heart, Lung, and Blood Institute (2000). Morbidity and Mortality: 2000 Chart Book on Cardiovascular, Lung, and Blood Diseases. National Institutes of Health, Bethesda, MD.Google Scholar
  8. [8]
    Marder, D., P. Targonski, P. Orris, V. Persky, and W. Addington (1992). Effect of racial and socioeconomic factors on asthma mortality in Chicago. Chest, 101, 4265S–4429S.Google Scholar
  9. [9]
    Carr, W., L. Zeitel, and K.B. Weiss (1992). Asthma hospitalization and mortality in New York City. American Journal of Public Health, 82, 59–65.PubMedGoogle Scholar
  10. [10]
    Martinez, F.D., A.L. Wright, L.M. Taussig, C.J. Holberg, M. Halonen, and W.J. Morgan (1995). Asthma and wheezing in the first six years of life. The Group Health Medical Associates. New England Journal of Medicine, 332, 133–138.CrossRefPubMedGoogle Scholar
  11. [11]
    Kattan, M., H. Mitchell, P. Eggleston, P. Gergen, E. Crain, S. Redline, K. Weiss, R. Evans 3rd, R. Kaslow, C. Kercsmar, F. Leickly, F. Malveaux, and H.J. Wedner (1997). Characteristics of inner-city children with asthma: The National Cooperative Inner-City Asthma Study. Pediatric Pulmonology, 24, 253–262.CrossRefPubMedGoogle Scholar
  12. [12]
    Kitch, B.T., G. Chew, H.A. Burge, M.L. Muilenberg, S.T. Weiss, T.A. Platts-Mills, G. O’Connor and D.R. Gold (2000). Socioeconomic predictors of high allergen levels in homes in the greater Boston area. Environmental Health Perspectives, 108, 301–307.PubMedGoogle Scholar
  13. [13]
    Evans, R. (1992). Asthma among minority children. A growing problem. Chest, 101(Suppl), 368S–371S.PubMedGoogle Scholar
  14. [14]
    Gottlieb, D.J., A.S. Beiser, and G.T. O’Connor (1995). Poverty, race, and medication use are correlates of asthma hospitalization rates. A small area analysis in Boston. Chest, 108, 28–35.PubMedGoogle Scholar
  15. [15]
    Weiss, K.B., E.N. Grant, and T. Li (1999). The effects of asthma experience and social demographic characteristics on responses to the Chicago Community Asthma Survey-32. Chicago Asthma Surveillance Initiative Project Team. Chest, 116(Suppl 1), 183S–189S.PubMedGoogle Scholar
  16. [16]
    Stableforth, D.E. (1987). Asthma mortality and physician competence. Journal of Allergy and Clinical Immunology, 80, 463–466.CrossRefPubMedGoogle Scholar
  17. [17]
    Kravis, L.P. (1987). An analysis of fifteen childhood asthma fatalities. Journal of Allergy and Clinical Immunology, 80, 467–472.CrossRefPubMedGoogle Scholar
  18. [18]
    Strunk, R.C., D.A. Mrazek, G.S.W. Fuhrmann, and J.F. LaBrecque (1985). Deaths from asthma in childhood. Can they be predicted? Journal of the American Medical Association, 254, 1193.CrossRefPubMedGoogle Scholar
  19. [19]
    Barnes, P.J. (1989). A new approach to the treatment of asthma. Department of Thoracic Medicine, Brompton Hospital, London, United Kingdom. New England Journal of Medicine, 321, 1517–1527.PubMedGoogle Scholar
  20. [20]
    Barnes, P.J. and I. Adcock (1993). Anti-inflammatory actions of steroids: molecular mechanisms. Trends in Pharmacological Sciences, 14, 436–441CrossRefPubMedGoogle Scholar
  21. [21]
    Pearlman, D.S., P. Chervinsky, C. LaForce, J.M. Seltzer, D.L. Southern, J.P. Kemp, RJ. Dockhorn, J. Grossman, R.F. Liddle, and S.W. Yancey (1992). A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. New England Journal of Medicine, 327, 1420–1425.PubMedGoogle Scholar
  22. [22]
    Henderson, W.R., Jr. (1994). Role of leukotrienes in asthma. Annals of Allergy, 72, 272–278.PubMedGoogle Scholar
  23. [23]
    Buchner, D.A., L.T. Butt, A. De Stefano, B. Edgren, A. Suarez, and R.M. Evans (1998). Effects of an asthma management program of the asthmatic member: Patient centered results of a 2 year study in a managed care organization. American Journal of Managed Care, 4, 1288–1297.PubMedGoogle Scholar
  24. [24]
    Hammarquist, C., M.L. Burr, and P.C. Gotzsche for the Cochrane Airways Group (2001). House dust mite control measures for asthma. Cochrane Database of Systematic Reviews, Issue 1.Google Scholar
  25. [25]
    Peat, J.K. and J. Li (1999). Reversing the trend: Reducing the prevalence of asthma. Journal of Allergy and Clinical Immunology, 130, 1–10.Google Scholar
  26. [26]
    Custovic, A., S.C.O. Taggart, H.C. Francis, M.D. Chapman, and A. Woodcock (1995). Exposure to house dust mite allergens and the clinical activity of asthma. Journal of Allergy and Clinical Immunology, 98, 64–72.Google Scholar
  27. [27]
    Durham, S.R. (1996). Allergen avoidance measures. British Thoracic Society. Respiratory Medicine, 90, 441–5.CrossRefPubMedGoogle Scholar
  28. [28]
    Watson, W.T.A., A.B. Becker, and F.E.R. Simons (1993). Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. Journal of Allergy and Clinical Immunology, 91, 97–101.CrossRefPubMedGoogle Scholar
  29. [29]
    Pedersen, B., R. Dahl, N. Lindqvist, and N. Mygind (1990). Nasal inhalation of the glucocorticoid budesonide from a spacer for the treatment of patients with pollen rhinitis and asthma. Allergy, 45, 451–456.PubMedGoogle Scholar
  30. [30]
    Grant, J.A., C.F. Nicodemus, S.R. Findlay, MM. Glovsky, J. Grossman, H. Kaiser, E.O. Meltzer, D.Q. Mitchell, D. Pearlman, and J. Selner (1995). Clinical aspects of allergic disease. Cetrizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 95, 923–932.CrossRefPubMedGoogle Scholar
  31. [31]
    Corren, J., A. Harris, D. Aaronson, W. Beaucher, R. Berkowitz, E. Bronsky, R. Chen, P. Chervinsky, R. Cohen, J. Fourre, J. Grossman, E. Meltzer, A. Pedinoff, W. Strieker, and A. Wanderer (1997). Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. Journal of Allergy and Clinical Immunology, 100, 781–788.CrossRefPubMedGoogle Scholar
  32. [32]
    Parmley, W.W. (1994). Clinical practice guidelines: does the cookbook have enough recipes? Journal of the American Medical Association, 272, 1374–1375.CrossRefPubMedGoogle Scholar
  33. [33]
    Ellrodt, A.G., L. Conner, M. Riedinger, and S. Weingarten (1995). Measuring and improving physician compliance with clinical practice guidelines: a controlled interventional trial. Annals of Internal Medicine, 122, 277–282.PubMedGoogle Scholar
  34. [34]
    Grimshaw, K., N. Freemantle, S. Wallace, I. Russell, B. Herwitz, I. Watt, A. Long, and T. Sheldon (1995). Developing and implementing clinical practice guidelines. Quality in Health Care, 4, 55–64.PubMedGoogle Scholar
  35. [35]
    Adams, R.J., A. Fuhlbrigge, T. Guilbert, P. Lozano, and F. Martinez (2002). Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. Journal of Allergy and Clinical Immunology, 110, 58–64.CrossRefPubMedGoogle Scholar
  36. [36]
    Windsor, R.A., W.C. Bailey, J.M. Richards Jr., B. Manzella, S.J. Soong, and M. Brooks (1990). Evaluation of the efficacy and cost-effectiveness of health education methods to increase medication adherence among adults with asthma. American Journal of Public Health, 80, 1519.PubMedGoogle Scholar
  37. [37]
    Gallefoss, F. and P.S. Bakke (2001). Cost-effectiveness of self-management in asthmatics: a 1-yr follow-up randomized, controlled trial. European Respiratory Journal, 17, 206–213.CrossRefPubMedGoogle Scholar
  38. [38]
    Wilson Pessano, S.R., P. Scamagas, G.M. Arsham, L. Chardon, S. Coss, D.F. German, and G.W. Hughes (1987). An evaluation of approaches to asthma self-management education for adults: the AIR/Kaiser Permanente study. Journal of Health Education, 14, 333–343.Google Scholar
  39. [39]
    Clark, N.M., C.H. Feldman, D. Evans, M.J. Levison, Y. Wasilewski, and R.B. Mellins (1986). The impact of health education on frequency and cost of health care use by low income children with asthma. Journal of Allergy and Clinical Immunology, 78, 108–115.CrossRefPubMedGoogle Scholar
  40. [40]
    Lewis, C.E., G. Rachelefsky, M.A. Lewis, A de la Sota, and M. Kaplan (1984). A randomized trial of A.C.T. (asthma care training) for kids. Pediatrics, 74, 478–486.PubMedGoogle Scholar
  41. [41]
    Tierce, J.C., W. Meller, B. Berlow, and W.C. Gerth (1989). Assessing the cost of albuterol inhalers in the Michigan and California Medicaid programs: a total cost-of-care approach. Clinical Therapeutics, 11, 53.PubMedGoogle Scholar
  42. [42]
    Campbell, L.M., R.J. Simpson, M.L. Turbitt, and P.D.I. Richardson (1993). A comparison of the cost-effectiveness of budesonide 400 mg/day and 800 mg/day in the management of mild-to-moderate asthma in general practice. British Journal of Medical Economics, 6, 67–74.Google Scholar
  43. [43]
    Ross, R.N., M. Morris, S.R. Sakowitz, and B.A. Berman (1988). Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record based study. Clinical Therapeutics, 10, 188–203.PubMedGoogle Scholar
  44. [44]
    Rutten-van-Molken, M.P.M.H., E.K.A. Van Doorslaer, M.C.C. Jansen, H.A.M. Kerstjens, and F.F.H. Rutten (1995). Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 151, 975–982.PubMedGoogle Scholar
  45. [45]
    Connett, G.J., W. Lenney, and S.M. McConchie (1993). The cost-effectiveness of budesonide in severe asthmatics aged one to three years. British Journal of Medical Economics, 6, 127–270.Google Scholar
  46. [46]
    Gold, M.R., J.E. Siegel, L.B. Russel, and M.C. Weinstein, Eds. (1996). Report of the Panel on Cost-effectiveness in Health and Medicine. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York.Google Scholar
  47. [47]
    Kuntz, K.M., B.T. Kitch, A.L. Fuhlbrigge, A.D. Paltiel, P.J. Neumann, and S.T. Weiss (2002). A novel approach to defining the relationship between lung function and symptom status in asthma. Journal of Clinical Epidemiology, 55, 11–18.CrossRefPubMedGoogle Scholar
  48. [48]
    Fuhlbrigge, A.L., B.T. Kitch, A.D. Paltiel, K.M. Kuntz, P.J. Neumann, D.W. Dockery, and S.T. Weiss (2001). FEV1 is associated with risk of asthma attacks in a pediatric population. Journal of Allergy and Clinical Immunology, 107, 61–67.CrossRefPubMedGoogle Scholar
  49. [49]
    Neumann, P.J., K. Blumenschein, A. Zillich, M. Johannesson, K.M. Kuntz, R.H. Chapman, S.T. Weiss, B.T. Kitch, A.L. Fuhlbrigge, and A.D. Paltiel (2000). Relationship between FEV1% predicted and utilities in adult asthma [Abstract]. Medical Decision Making, 20, 488.Google Scholar
  50. [50]
    Paltiel, A.D., A.L. Fuhlbrigge, B.T. Kitch, B. Liljas, S.T. Weiss, P.J. Neumann, and K.M. Kuntz (2001). Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. Journal of Allergy and Clinical Immunology, 108, 39–46.CrossRefPubMedGoogle Scholar
  51. [51]
    Sullivan, S.D., A. Elixhauser, A.S. Buist, B.R. Luce, J. Eisenberg, and K.B. Weiss (1996). National Asthma Education and Prevention Program working group report on the cost-effectiveness of asthma care. American Journal of Respiratory and Critical Care Medicine, 154, S84–S95.PubMedGoogle Scholar
  52. [52]
    United States Bureau of the Census (1998). Statistical Abstract of the United States: 1998. Washington, DC.Google Scholar
  53. [53]
    Beck, J.R. and S.G. Pauker (1983). The Markov process in medical prognosis. Medical Decision Making, 3, 419–458.PubMedGoogle Scholar
  54. [54]
    Sonnenberg, F.A. and J.R. Beck (1993). Markov models in medical decision making: a practical guide. Medical Decision Making, 13, 322–338.PubMedGoogle Scholar
  55. [55]
    Crane, J., N. Pearce, C. Burgess, K. Woodman, B. Robson, and R. Beasley (1992). Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. International Journal of Epidemiology, 21, 737–744.PubMedGoogle Scholar
  56. [56]
    Ortega, A.N., K.D. Belanger, M.B. Bracken, and B.P. Leaderer (2001). A childhood asthma severity scale: symptoms, medications, and health care visits. Annals of Allergy, Asthma, and Immunology, 86, 405–413.PubMedGoogle Scholar
  57. [57]
    National Asthma Education and Prevention Program (1991). Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report. U.S. Department of Health and Human Services, Washington, DC, Publication # 91-3042.Google Scholar
  58. [58]
    Enright, P.L., M.D. Lebowitz, and D.W. Cockroft (1994). Physiologic measures: pulmonary function tests. Asthma outcomes. American Journal of Respiratory and Critical Care Medicine, 149, S9–S20.PubMedGoogle Scholar
  59. [59]
    Enright, P.L., L.R. Johnson, J.E. Connett, H. Voelker, and A.S. Buist (1991). Spirometry in the Lung Health Study. Methods and quality control. American Review of Respiratory Disease, 143, 1215–1221.PubMedGoogle Scholar
  60. [60]
    Kitch, B.T., A.L. Fuhlbrigge, K.M. Kuntz, P.J. Neumann, A.D. Paltiel, B. Rijeken, B. Schouten, D.S. Postma, and S.T. Weiss (1999). Relationship between FEV1 and subsequent asthma attacks. American Journal of Respiratory and Critical Care Medicine, 159, A135.Google Scholar
  61. [61]
    Thomas, P., R.N. Ross, and J.R. Farrar (1996). A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma. Clinical Therapeutics, 18, 939–952.CrossRefPubMedGoogle Scholar
  62. [62]
    Donahue, J.G., S.T. Weiss, J.M. Livingston, M.A. Goetsch, D.K. Greineder, and R. Platt (1997). Inhaled steroids and the risk of hospitalization for asthma. Journal of the American Medical Association, 277, 887–891.CrossRefPubMedGoogle Scholar
  63. [63]
    Finkelstein, J.A., M.B. Barton, J.G. Donahue, P. Algatt-Bergstrom, L.E. Markson, and R. Platt (2000). Comparing asthma care for Medicaid and non-Medicaid children in an HMO. Archives of Pediatrics and Adolescent Medicine, 154, 563–568.PubMedGoogle Scholar
  64. [64]
    Rutten-van-Molken, M.P.M.H., E.K.A. Van Doorslaer, M.C.C. Jansen, H.A.M. Kerstjens, and F.F.H. Rutten (1995). Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 151, 975–982.PubMedGoogle Scholar
  65. [65]
    Revicki, D.A., N.K. Leidy, F. Brennan-Diemer, S. Sorensen, and A. Togias (1998). Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest, 114, 998–1007.PubMedGoogle Scholar
  66. [66]
    Neumann, P.J., K. Blumenschein, A. Zillich, M. Johannesson, K.M. Kuntz, R.H. Chapman, S.T. Weiss, B.T. Kitch, A.L. Fuhlbrigge, and A.D. Paltiel (2000). Relationship between FEV1% predicted and utilities in adult asthma. Medical Decision Making, 20, 488.Google Scholar
  67. [67]
    Pearlman, D.S., W. Stricker, S. Weinstein, G. Gross, P. Chervisnsky, A. Woodring, B. Prillaman, and T. Shah (1999). Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Annals of Allergy, Asthma, and Immunology, 82, 257–265.PubMedGoogle Scholar
  68. [68]
    Noonan, M., P. Chervinsky, W.W. Busse, S.C. Weisberg, J. Pinna, B.P. de Boisblanc, H. Boltansky, D. Pearlman, L. Rephser, D. Kellerman (1995). Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. American Journal of Respiratory and Critical Care Medicine, 152, 1467–1473.PubMedGoogle Scholar
  69. [69]
    Bel, E.H., M.C. Timmers, J. Hermans, J.H. Dijkman, and P.J. Sterk (1990). The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. American Review of Respiratory Disease, 141, 21–28.PubMedGoogle Scholar
  70. [70]
    Fahy, J.V. and H.A. Boushey (1998). Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. European Respiratory Journal, 11(6), 1240–1247.CrossRefPubMedGoogle Scholar
  71. [71]
    Galant, S.P., M. Lawrence, E.O. Meltzer, M. Tomasko, K.A. Baker, and D.J. Kellerman (1996). Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Annals of Allergy, Asthma, and Immunology, 77, 112–118.PubMedGoogle Scholar
  72. [72]
    Kemp, J., A.A. Wanderer, J. Ramsdell, D.L. Southern, S. Weiss, D. Aaronson, and J. Grossman (1999). Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Annals of Allergy, Asthma, and Immunology, 82, 463–471.PubMedGoogle Scholar
  73. [73]
    Li, J.T., L.B. Ford, P. Chervinsky, S.C. Weisberg, D.J. Kellerman, K.G. Faulkner, N.E. Herje, A. Hamedani, S.M. Harding, and T. Shah (1999). Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. Journal of Allergy and Clinical Immunology, 103, 1062–1068.PubMedGoogle Scholar
  74. [74]
    McFadden, E.R., T.B. Casale, T.B. Edwards, J.P. Kemp, W.J. Metzger, H.S. Nelson, W.W. Storms, and M.J. Neidl (1999). Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. Journal of Allergy and Clinical Immunology, 104, 46–52.CrossRefPubMedGoogle Scholar
  75. [75]
    Meltzer, E.O., H.A. Orgel, E.F. Ellis, H.N. Eigen, and M.P. Hemstreet (1992). Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma. Journal of Allergy and Clinical Immunology, 90, 2–11.PubMedGoogle Scholar
  76. [76]
    Nathan, R.A., J.L. Pinnas, H.J. Schwartz, J. Grossman, S.W. Yancey, A.H. Emmett, and K.A. Rickard (1999). A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Annals of Allergy, Asthma, and Immunology, 82, 521–529.PubMedGoogle Scholar
  77. [77]
    Osterman, K., M. Carlholm, J. Ekelund, J. Kiviloog, K. Nikander, L. Nilholm, P. Salomonsson, V. Strand, P. Venge, and O. Zetterstrom (1997). Effect of 1 year daily treatment with 400 microg budesonide (Pulmicort Turbuhaler) in newly diagnosed asthmatics. European Respiratory Journal, 10, 2210–2215.CrossRefPubMedGoogle Scholar
  78. [78]
    Peden, D.B., W.E. Berger, M.J. Noonan, M.J. Noonan, M.R. Thomas, V.L. Hendricks, A.G. Hamedani, P. Mahajan, and K.W. House (1998). Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. Journal of Allergy and Clinical Immunology, 102, 32–38.CrossRefPubMedGoogle Scholar
  79. [79]
    Reed, C.E., K.P. Offord, H.S. Nelson, J.T. Li, and D.G. Tinkelman (1998). Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. Journal of Allergy and Clinical Immunology, 101, 14–23.CrossRefPubMedGoogle Scholar
  80. [80]
    Sheffer, A.L., C. LaForce, P. Chervinsky, D. Pearlman, and A. Schaberg (1996). Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. Family Practice, 42, 369–375.Google Scholar
  81. [81]
    Simons, F.E. (1997). A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. New England Journal of Medicine, 337, 1659–1665.CrossRefPubMedGoogle Scholar
  82. [82]
    Tinkelman, D.G., C.E. Reed, H.S. Nelson, and K.P. Offord (1993). Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics, 92, 64–77.PubMedGoogle Scholar
  83. [83]
    Evans, R. 3rd, D.I. Mullally, R.W. Wilson, P. J. Gergen, H.M. Rosenberg, J.S. Grauman, F.M. Chevarley, and M. Feinleib (1987). National Trends in Morbidity and Mortality of Asthma in the US. Chest, 91, 65S–73S.PubMedGoogle Scholar
  84. [84]
    U.S. Bureau of the Census (1997). Statistical Abstract of the United States: 1997. Washington, DC.Google Scholar
  85. [85]
    Serra-Batlles, J., V. Plaza, E. Morejon, A. Comella, and J. Brugues (1998). Costs of asthma according to the degree of severity. European Respiratory Journal, 12, 1322–1326.CrossRefPubMedGoogle Scholar
  86. [86]
    Stanford, R., T. McLaughlin, and L.J. Okamoto (1999). The cost of asthma in the emergency department and hospital. American Journal of Respiratory and Critical Care Medicine, 160, 211–215.PubMedGoogle Scholar
  87. [87]
    Lewis, C.E., G. Rachelefsky, M.A. Lewis, A. de la Sota, and M. Kaplan (1984). A randomized trial of A.C.T. (asthma care training) for kids. Pediatrics, 74, 478–486.PubMedGoogle Scholar
  88. [88]
    Ross, R.N., M. Morris, S.R. Sakowitz, and B.A. Berman (1988). Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study. Clinical Therapeutics, 10, 188–203.PubMedGoogle Scholar
  89. [89]
    Weiss, K.B., P.J. Gergen, and T.A. Hodgson (1992). An economic evaluation of asthma in the United States. New England Journal of Medicine, 326, 862–866.PubMedGoogle Scholar
  90. [90]
    Coventry, J.A., M.S. Weston, and P.M. Collins (1996). Emergency room encounters of pediatric patients with asthma: cost comparisons with other treatment settings. Journal of Ambulatory Care Management, 19, 9–21PubMedGoogle Scholar
  91. [91]
    Segal, R., L.D. Ried, and J. Mackowiak (1995). Cost of asthma illness: Emergency department visits without admission. Pharmacy Practice Management Quarterly, 15, 72–82.PubMedGoogle Scholar
  92. [93]
    Barnes, P.J., S. Pedersen, and W.W. Busse (1993). Efficacy and safety of inhaled corticosteroids. New developments. American Journal of Respiratory and Critical Care Medicine, 157, S1–S53.Google Scholar
  93. [94]
    O’Byrne, P.M. and S. Pedersen (1998). Measuring efficacy and safety of different inhaled corticosteroid preparations. Journal of Allergy and Clinical Immunology, 102, 879–886.PubMedGoogle Scholar
  94. [95]
    Chapman, R.H., P.W. Stone, E.A. Sandberg, C. Bell, and P.J. Neumann (2000). A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Medical Decision Making, 20, 451–467.PubMedGoogle Scholar
  95. [96]
    Sippel, J.M., K.L. Pudula, W.M. Vollmer, A.S. Buist, and M.L. Osborne (1999). Association of smoking with hospital-based care and quality of life in patients with obstructive airway disease. Chest, 115, 691–696.CrossRefPubMedGoogle Scholar
  96. [97]
    Prescott, E., P. Lange, and J. Vestbo (1997). Effect of gender on hospital admission for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population. Copenhagen City Health Study Group. Thorax, 52, 287–289.PubMedGoogle Scholar
  97. [98]
    Lange, P., J. Parner, J. Bestbro, P. Schnohr, and G. Jensen (1998). A 15 year follow up study of ventilatory function in adults with asthma. New England Journal of Medicine, 339, 1194–1200.PubMedGoogle Scholar
  98. [99]
    Ulrik, C.S. and P. Lange (1994). Decline of Lung Function in Adults with Bronchial Asthma. American Journal of Respiratory and Critical Care Medicine, 150, 629–634.PubMedGoogle Scholar
  99. [100]
    Cook, D.G. and D.P. Strachan (1999). Health effects of passive smoking-10: Summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax, 54, 357–366.PubMedGoogle Scholar
  100. [101]
    Toogood, J.H., A.E. Markov, J. Baskerville, and C. Dyson (1993). Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. Journal of Allergy and Clinical Immunology, 91, 571–579.PubMedGoogle Scholar
  101. [102]
    Toogood, J.H. (1998). Inhaled steroid asthma treatment: ‘Primum non nocere’. Canadian Respiratory Journal, 5, 50A–53A.PubMedGoogle Scholar
  102. [103]
    Niewoehner, C.B. and D.E. Niewoehner (1999). Steroid-induced osteoporosis. Are your asthmatic patients at risk? Postgraduate Medicine, 105, 79–83, 87–8, 91.PubMedGoogle Scholar
  103. [104]
    Christensen-Szalanski, J.J. and G.B. Northcraft (1985). Patient compliance behavior: the effect of time on patients’ valued of treatment regiments. Social Science and Medicine, 21, 263–273.PubMedGoogle Scholar
  104. [105]
    Greenburg, R.N. (1984). Overview of patient compliance with medication dosing: a literature review. Clinical Therapeutics, 6, 592–599.Google Scholar
  105. [106]
    Donahue, J.G., S.T. Weiss, J.M. Livingston, M.A. Goetsch, D.K. Greineder, and R. Platt (1997). Inhaled steroids and the risk of hospitalization for asthma. Journal of the American Medical Association, 277, 887–891.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • A. David Paltiel
    • 1
  • Karen M. Kuntz
    • 2
  • Scott T. Weiss
    • 3
  • Anne L. Fuhlbrigge
    • 3
  1. 1.Department of Epidemiology and Public HealthYale School of MedicineNew Haven
  2. 2.Department of Health Policy and ManagementHarvard School of Public HealthBoston
  3. 3.Channing Laboratory, Department of MedicineHarvard Medical School Brigham and Women’s HospitalBoston

Personalised recommendations